Track topics on Twitter Track topics that are important to you
PharmSource Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook 2018 Edition
The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction especially for small to midsized CMOs in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities. This report, the 2018 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability. We also assess the outlook for the industry. This report is an improvement over previous reports because it utilizes GlobalData's Intelligence Center Drug database to provide deeper analysis of the industry.
Most commercial dose companies have solid dose manufacturing facilities, as new products become molecularly complex issues arise such as those surrounding bioavailability and formulation delivery technologies are becoming increasingly important for products that are often have poor solubility or are highly potent Hickman et al. 2018. As batches are becoming smaller due to an increasing use of orphan drugs and drugs for patient sub populations such as pediatrics, the ability for flexible and smallscale is becoming particularly desirable. These two trends will affect consolidation trends for CMOs as certain technologies are increasingly sought after and will also affect dose related revenue growth as many CMOs will not have the capabilities to provide the desired service for a changing drug products in a decreasing patient population. PharmSource predicts that dose related CMO revenues will grow more slowly than for their API counterparts. Many dose CMOs will have to improve their formulation and drug delivery technologies to compete for clients with products that are often have poor solubility or are highly potent
Key Questions Answered
What is the geographic reach of Dose CMOs?
What are the 2017 revenues generated by Contract dose manufacturing industry?
What are the components of revenue change for Contract Dose Manufacturers?
What is the breakdown of 2017 revenues by different dosage forms?
What are the characteristics of the largest dose CMOs?
How did the revenue growth of Contract Dose manufacturers in 2017 compare to Contract API manufacturers?
What proportion of approved NDAs have had their Dose manufacture outsourced between 20082017?
What is the outlook for the dose CMO industry?
What Dose CMO MA deals occurred in 2017?
To describe and evaluate the dose market, segmented by type of growth and dosage form contributions
To describe and assess the MA environment for Dose CMOs
To assess the outlook for buyers and sellers of contract manufacturing services for commercial dose, including the supply/demand balance.
Overview of dose contract revenue market size, the components of growth and dosage form specific revenues for CMOs providing pharmaceutical finished dosage form for supply to the highly regulated markets of the US, Canada, EU and Japan.
Detailed view of dose CMO MA deals and services gained for commercial dose manufacturing, established from the PharmSource Contract Service Providers database.
Assessment of dose CMO industry size and structure.
Characterising types of dosage form manufacture provided by the leading dose CMOs.
Reasons to buy
This 47page report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry PharmSource's Database of Contract Service Providers and Financial Database this analysis is driven by a proprietary model of the dose manufacturing industry, which is continuously updated and refined. The 8 tables and 10 figures throughout the report illustrate major points and trends. This report is required reading for
CMO executives and strategic decisionmakers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
Private equity investors: they can deeper understanding of the dose CMO market and important insight for identifying potential investment targets.NEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...